Research programme: CD8 Treg modulators - Mozart Therapeutics
Alternative Names: Research programme: CD8 T regulatory cell modulators - Mozart TherapeuticsLatest Information Update: 16 May 2022
At a glance
- Originator Mozart Therapeutics
- Class Anti-inflammatories
- Mechanism of Action CD8 positive T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammatory bowel diseases
Most Recent Events
- 10 May 2022 Preclinical trials in Autoimmune disorders in USA (unspecified route), prior to May 2022
- 10 May 2022 Preclinical trials in Inflammatory bowel diseases in USA (unspecified route), prior to May 2022
- 26 Oct 2021 Mozart Therapeutics in-license technology related to T cell biology from Stanford University School of Medicine